EUCTR2012-004131-23-GB进行中（未招募）1 期
A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted state, using a novel intragastric and oesophageal pH catheter. - Gaviscon Double Action pH monitoring study.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1)Informed consent has been obtained.
- •2)Age: = 18 years, = 50 years.
- •3)Sex: male or female subjects.
- •4)Status: healthy subjects.
- •5)Body Mass Index (BMI): between 18.5 and 24.9.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)A history of gastro-oesophageal reflux or active gastrointestinal disease (gastroduodenal ulcer, gastrointestinal haemorrhage, mechanical obstruction or perforation) within the last year.
- •2)Clinically significant allergic, pulmonary, neurological, renal, hepatic, cardiovascular, psychiatric, metabolic, endocrine, or haematological disease.
- •3)A history of basal skull fracture or who have undergone trans-sphenoidal surgery.
- •4)Have been hospitalised within the previous three months for major surgery or medical illness.
- •5)A clinically significant illness within the previous 4 weeks.
- •6)Have taken any prescription medication or non-prescription medication within the last seven days, prior to the screening visit, which the Principal Investigator considers may interfere with the study.
- •7)Have taken antacids, H2 antagonists, motility stimulants (e.g prokinetics, macrolide antibiotics such as erythromycin and azithromycin, and 5HT agonists such as sumatriptan) or other medicines for relief of symptoms of acid reflux disease 2 weeks prior to enrolment in the study and during the study and/or have taken proton pump inhibitors 4 weeks prior to enrolment into the study and during the study.
- •8)Are taking any of the following medications: antihistamines, tetracyclines, antifungals, digoxin, fluoroquinolone, iron salt, neuroleptics, thyroxine, penicillamine, beta-blockers (atenolol, metoprolol, propranolol), glucocorticoid, chloroquine, and biphosphonates.
- •9)Have a drug hypersensitivity, which in the opinion of the Principal Investigator might interfere with the study.
- •10)Any previous history of allergy or known intolerance to any of the Investigational Medicinal Product’s (IMP) or following formulation constituents: e.g. sodium alginate, parabens (methyl and propyl), glucose syrup, carbomer and xanthan gum.
- •11)Those with known hypophosphataemia.
- •12)Those on a highly restricted salt diet.
- •13)Those with, or a history of, hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
- •14)A current or recent (within one year) history of alcohol abuse or significant abuse of any legal or illegal drugs, substances and solvents.
- •15)Regularly (weekly) consume excessive amounts of alcohol (> 8 units for men and > 6 units for women in one sitting, excessive amounts as defined by the UK National Office of Statistics).
- •16)Have consumed more than 2 units of alcohol per day in the 7 days prior to the screening visit.
- •17)Regular consumption of excessive quantities caffeine (> 6 cups of tea, coffee or cola per day), according to the Investigator’s judgement.
- •18)Tobacco use is > 6 cigarettes per day or equivalent or unable to refrain from tobacco/ nicotine use during the study periods.
- •19)Female subjects of childbearing potential who, for the duration of the study, are either unwilling or unable to take adequate contraceptive precautions (as defined in the protocol or are unwilling to be sexually abstinent (as defined in the protocol).
- •20)Pregnancy or lactating mother.
- •21)Those who are known to be unable to tolerate insertion of the catheter or endoscope.
研究者
相似试验
已完成
不适用
A randomized, single center, 2-way crossover, comparator controlled Phase I trial to evaluate the effect of a new analgesic on ventilation in healthy subjectspijnnociceptive painpainNL-OMON32792Grunenthal12
已完成
不适用
A single-center, randomized, crossover and retrospective pivotal trial to evaluate the efficacy of VUNO Med – Chest X-ray in screening of abnormalities on chest radiographDiseases of th respiratory systemKCT0004147Vuno228
已完成
3 期
0.9% saline vs. Plasma-Lyte 148 for Intensive Care Fluid Therapy. (the SPLIT study)Intravenous Fluid Management in Critical IllnessCardiovascular - Other cardiovascular diseasesAnaesthesiology - Other anaesthesiologyInfection - Other infectious diseasesACTRN12613001370796Medical Research Institute of New Zealand2,500
进行中（未招募）
不适用
Study to investigate the effect of Gaviscon® Double Action, Gaviscon® Advance and Placebo Liquid Vs no treatment on the acid pocket.EUCTR2012-000678-44-GBReckitt Benckiser Healthcare (UK) Ltd
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.Hypercholesterolemia and Mixed DyslipidemiaMedDRA version: 9.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2007-002516-26-FRaboratoires Merck Sharp & Dohme-Chibret2,370